Sylvie Castaigné

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste et al. · Blood · 2010 · 1.6K citations · Full text

Medicine, Hematology, Oncology +10

All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results [see comments]

Sylvie Castaigné, Christine Chomienne, MT Daniel et al. · Blood · 1990 · 1.2K citations · Full text

Medicine, Hematology, Oncology +11

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Sylvie Castaigné, Cécile Pautas, Christine Terré et al. · The Lancet · 2012 · 995 citations

Medicine, Hematology, Pharmacology +10

A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

Pierre Fenaux, Claude Chastang, Sylvie Chevret et al. · Blood · 1999 · 745 citations

Medicine, Hematology, Oncology +12

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

Frédéric Peyrade, Fabrice Jardin, Catherine Thiéblemont et al. · The Lancet Oncology · 2011 · 545 citations

Medicine, Immunology, Oncology +15